Development Pipeline

Two therapeutic verticals from a single chemistry platform.

Program
Indication
DiscoveryLead Opt.IND-EnablingPhase 1Phase 2
SNM-01 Lead

Nucleoside analog — Oncology

Pancreatic, NSCLC, TNBC, CRC
✓ ◐ ○ ○ ○
SNM-02

Nucleoside analog — Oncology (Backup)

Ovarian, Additional Cancers
✓ ○ ○ ○ ○
SNM-AV Dual-Use

Nucleoside analog — Antiviral

CHIKV, VEEV, Dengue, Mayaro
◐ ○ ○ ○ ○
✓ Complete ◐ Ongoing ○ Planned

SNM-01: Lead Oncology

In vitro data complete across 12+ cell lines. Currently in lead optimization and IND-enabling study design.

SNM-02: Alt Focus

Second-generation compound addressing optimization across additional cancers.

SNM-AV: Antiviral

Broad-spectrum activity against alphaviruses and flaviviruses. BARDA pathway potential.

$100B+ Addressable Market

One chemistry platform targeting universal resistance mechanisms.

Oncology

Solid Tumors

$78B+
Global Market

Pancreatic, colorectal, NSCLC, triple-negative breast — addressing multi-layered resistance.

  • Basket-trial ready across GEM-resistant indications
  • Salvage/2L+ positioning where IO and standard agents fail
  • Combination potential with checkpoint inhibitors
Comparable Deals: Ipsen/Onivyde ($1B+), Celgene/Abraxane ($1B+ peak)
Infectious Disease

Emerging Virals

$25B+
Antiviral Market

Alphaviruses (CHIKV, VEEV, Mayaro) and flaviviruses — pandemic-ready where no approved antivirals exist.

  • No approved drugs for CHIKV, VEEV, or Mayaro
  • BARDA/biodefense procurement pathway eligible
  • Variant-agnostic mechanism
Precedent: Gilead/Remdesivir ($5.6B peak), Merck/Molnupiravir ($5.7B in 2022)

"The most valuable platforms in biotech history — Gilead's nucleoside chemistry, Moderna's mRNA — were built by teams who understood the underlying chemistry at an atomic level. Our founders built key components of both."

One Platform • Unlimited Potential